Ahmet Arman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmet Arman has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Pınar Ata
Department of Medical Genetics, Marmara University School of Medicine, Istanbul, Turkey
5 shared publications Ajda Coker
3 shared publications- Ceren Alavanda
Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
3 shared publications Edward O List
Ohio University
3 shared publicationsEdward O. List
Ohio University Heritage College of Osteopathic Medicine
3 shared publications- Abdullah Bereket
Department of Pediatric Endocrinology, Marmara University Faculty of Medicine, İstanbul, Türkiye
2 shared publications
Latest Publications
- 30 June 2026
- Published by Marmara University in International Journal of Advances in Engineering and Pure Sciences
- Vol. 38 (2) , 281-288
Association between Multiple Sclerosis and Interleukin-18 Gene Polymorphisms (-137 G/C, -607 C/A and -656 G/T) in Turkish Population
ObjectiveMultiple sclerosis (MS) is a complex disease of the central nervous system caused by both genetic and environmental factors. This study aimed to determine whether the interleukin-18 (IL-18) gene promoter polymorphisms -137 G/C, -607 C/A, and -656 G/T are associated with MS in the Turkish population. MethodsA total of 310 patients diagnosed with multiple sclerosis based on clinical criteria and 220 healthy controls were included in this study. Genotyping of IL-18 -137 G/C was performed by allele-specific PCR (AS-PCR), and -607 C/A and -656 G/T were genotyped by PCR-restriction fragment length polymorphism (PCR-RFLP) using Tru1I and MwoI enzymes respectively. Data were analyzed by the chi-square test to compare genotype and allele frequencies between groups, and odds ratios (OR) with 95% confidence intervals were calculated.ResultsA significant association was found between IL-18 -137 G/C polymorphism and MS (p
- 30 June 2026
- Published by Marmara University in International Journal of Advances in Engineering and Pure Sciences
- Vol. 38 (2) , 281-288
Association between Multiple Sclerosis and Interleukin-18 Gene Polymorphisms (-137 G/C, -607 C/A and -656 G/T) in Turkish Population
ObjectiveMultiple sclerosis (MS) is a complex disease of the central nervous system caused by both genetic and environmental factors. This study aimed to determine whether the interleukin-18 (IL-18) gene promoter polymorphisms -137 G/C, -607 C/A, and -656 G/T are associated with MS in the Turkish population. MethodsA total of 310 patients diagnosed with multiple sclerosis based on clinical criteria and 220 healthy controls were included in this study. Genotyping of IL-18 -137 G/C was performed by allele-specific PCR (AS-PCR), and -607 C/A and -656 G/T were genotyped by PCR-restriction fragment length polymorphism (PCR-RFLP) using Tru1I and MwoI enzymes respectively. Data were analyzed by the chi-square test to compare genotype and allele frequencies between groups, and odds ratios (OR) with 95% confidence intervals were calculated.ResultsA significant association was found between IL-18 -137 G/C polymorphism and MS (p
- 28 January 2026
- Published by Marmara University in Marmara Medical Journal
- Vol. 39 (1) , 1-5
Agarose-based long-range polymerase chain reaction assay for genotyping Turkish patients with Friedreich’s ataxia
Objective: An agarose-based long-range polymerase chain reaction (PCR) assay was performed on patients with a preliminary diagnosis of Friedreich’s ataxia (FA). It aimed to determine the repeat number in intron 1 of the FXN gene and to investigate the genotype-phenotype correlation. Patients and Methods: Nineteen cases participated in the study. Long-range PCR was performed under appropriate conditions using two custom-designed primer pairs (F1-R1 and F2-R2). The PCR products were run on an agarose gel, and guanine-adenine-adenine (GAA) repeat numbers were determined. Results: Biallelic GAA repeat expansions were detected in 6 patients. Four patients had typical FA. One had late-onset FA (LOFA). Another had very late-onset FA (VLOFA). All patients diagnosed with FA had ataxia and areflexia. The detected repeat numbers were approximately 190-1120 for F1-R1 and 170-1100 for F2-R2. The patient with LOFA had 190/1000 GAA repeats. The VLOFA patient had 290/290 GAA repeats. Conclusion: An earlier clinical onset correlated with higher GAA repeats. An agarose-based long-range PCR assay is a quick, low-cost, and effective way to determine GAA repeats. This study shows it can diagnose the disease and identify carriers.
- 28 January 2026
- Published by Marmara University in Marmara Medical Journal
- Vol. 39 (1) , 1-5
Agarose-based long-range polymerase chain reaction assay for genotyping Turkish patients with Friedreich’s ataxia
Objective: An agarose-based long-range polymerase chain reaction (PCR) assay was performed on patients with a preliminary diagnosis of Friedreich’s ataxia (FA). It aimed to determine the repeat number in intron 1 of the FXN gene and to investigate the genotype-phenotype correlation. Patients and Methods: Nineteen cases participated in the study. Long-range PCR was performed under appropriate conditions using two custom-designed primer pairs (F1-R1 and F2-R2). The PCR products were run on an agarose gel, and guanine-adenine-adenine (GAA) repeat numbers were determined. Results: Biallelic GAA repeat expansions were detected in 6 patients. Four patients had typical FA. One had late-onset FA (LOFA). Another had very late-onset FA (VLOFA). All patients diagnosed with FA had ataxia and areflexia. The detected repeat numbers were approximately 190-1120 for F1-R1 and 170-1100 for F2-R2. The patient with LOFA had 190/1000 GAA repeats. The VLOFA patient had 290/290 GAA repeats. Conclusion: An earlier clinical onset correlated with higher GAA repeats. An agarose-based long-range PCR assay is a quick, low-cost, and effective way to determine GAA repeats. This study shows it can diagnose the disease and identify carriers.
- Open Access
- 28 August 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (1) , 97-104
Growth Hormone Strongly Induces hSMN2 Promoter Driving Construct Gene Expression in Mammalian Cells
Growth Hormone Strongly Induces hSMN2 Promoter Driving Construct Gene Expression in Mammalian Cells - Journal of Clinical Research in Pediatric Endocrinology
- 28 August 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (1) , 97-104
Open AccessGrowth Hormone Strongly Induces hSMN2 Promoter Driving Construct Gene Expression in Mammalian Cells
Growth Hormone Strongly Induces hSMN2 Promoter Driving Construct Gene Expression in Mammalian Cells - Journal of Clinical Research in Pediatric Endocrinology
- 19 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e3021-e3030
Clinical and Molecular Genetic Characteristics of Patients with Hereditary Hypophosphatemia
Context: Hereditary hypophosphatemia (HH), is a rare condition related to decreased renal tubular phosphate reabsorption. Although X-linked hypophosphatemia or PHEX gene variant is the most frequent cause of HH, recent advances in next-generation sequencing (NGS) techniques enable the identification of genetic etiologies as a whole. Objective: This work aimed to identify genetic causes of HH using various genetic testing methods and to compare clinical features between FGF23-dependent and FGF23-independent HH groups. Methods: Fifty patients (24 males) from 39 unrelated families were included. Based on initial evaluation, PHEX gene sequencing was performed in patients with clinical and biochemical findings suggestive of FGF23-dependent HH. If sequencing showed no alterations, multiplex ligation-dependent probe amplification (MLPA) analysis for PHEX was conducted. Initially, a specific gene panel was performed for FGF23-independent HH or those in whom the PHEX gene showed no genetic alteration. Results: Genetic etiology was revealed in 43 patients from 33 families. PHEX gene variants (4 novel) were identified in 24 patients from 19 unrelated families (50%). SLC34A3 was the second most common (16.6%) and the rest were rarer causes of hypophosphatemia (DMP1 n = 3, SLC34A1 n = 2, CLCN5 n = 2, OCRL n = 2, FAM20C n = 1, SLC2A2 n = 1). When the genetically proven FGF23-dependent (n = 28) and FGF23-independent (n = 15) HH groups were compared for clinical and biochemical features; lower phosphate and TmP/GFR SDSs and higher ALP SDS with more severe clinical rickets were detected in FGF23-dependent group, whereas higher serum and urine calcium and lower PTH levels were detected in FGF23-independent group. Conclusion: The application of MLPA provided an additional explanatory value of 10% to the molecular etiology. However, 10% of the cases of HH still remain unexplained even after a comprehensive genetic work-up. Biochemical findings suggest distinct biochemical profiles between FGF23-dependent and FGF23-independent HH groups.
- 19 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e3021-e3030
Clinical and Molecular Genetic Characteristics of Patients with Hereditary Hypophosphatemia
Context: Hereditary hypophosphatemia (HH), is a rare condition related to decreased renal tubular phosphate reabsorption. Although X-linked hypophosphatemia or PHEX gene variant is the most frequent cause of HH, recent advances in next-generation sequencing (NGS) techniques enable the identification of genetic etiologies as a whole. Objective: This work aimed to identify genetic causes of HH using various genetic testing methods and to compare clinical features between FGF23-dependent and FGF23-independent HH groups. Methods: Fifty patients (24 males) from 39 unrelated families were included. Based on initial evaluation, PHEX gene sequencing was performed in patients with clinical and biochemical findings suggestive of FGF23-dependent HH. If sequencing showed no alterations, multiplex ligation-dependent probe amplification (MLPA) analysis for PHEX was conducted. Initially, a specific gene panel was performed for FGF23-independent HH or those in whom the PHEX gene showed no genetic alteration. Results: Genetic etiology was revealed in 43 patients from 33 families. PHEX gene variants (4 novel) were identified in 24 patients from 19 unrelated families (50%). SLC34A3 was the second most common (16.6%) and the rest were rarer causes of hypophosphatemia (DMP1 n = 3, SLC34A1 n = 2, CLCN5 n = 2, OCRL n = 2, FAM20C n = 1, SLC2A2 n = 1). When the genetically proven FGF23-dependent (n = 28) and FGF23-independent (n = 15) HH groups were compared for clinical and biochemical features; lower phosphate and TmP/GFR SDSs and higher ALP SDS with more severe clinical rickets were detected in FGF23-dependent group, whereas higher serum and urine calcium and lower PTH levels were detected in FGF23-independent group. Conclusion: The application of MLPA provided an additional explanatory value of 10% to the molecular etiology. However, 10% of the cases of HH still remain unexplained even after a comprehensive genetic work-up. Biochemical findings suggest distinct biochemical profiles between FGF23-dependent and FGF23-independent HH groups.
- Open Access
- 8 August 2024
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (2) , 126-135
Expanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings
Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.
- 8 August 2024
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (2) , 126-135
Open AccessExpanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings
Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e96979d7
PB2657: DIFFERENT TYPES OF LEUKEMIAS AND BLEEDING DISORDER DETECTED IN A TURKISH FAMILY WITH GERMLINE RUNX1 MUTATION FOR THE FIRST TIME.
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e96979d7
Open AccessPB2657: DIFFERENT TYPES OF LEUKEMIAS AND BLEEDING DISORDER DETECTED IN A TURKISH FAMILY WITH GERMLINE RUNX1 MUTATION FOR THE FIRST TIME.
- 31 October 2022
- Published by Marmara University in Marmara Medical Journal
- Vol. 35 (3) , 270-274
Vitamin D receptor gene polymorphisms in pediatric patients with leukemia-lymphoma: Does it have an impact on malignancy?
Objective: Genetic variations have been identified in specific regions of the Vitamin D receptor (VDR) gene and many studies were investigating whether these variations are associated with malignancy. Studies in the VDR on children are scarce. In this study, we aimed to investigate the VDR gene polymorphisms in pediatric patients with the diagnosis of leukemia and lymphoma. Patients and Methods: Of the 99 participants included in this cross-sectional study, 59 were control, 40 were patients. Fok-I, Bsm-I and Taq-I polymorphism of the VDR gene were investigated in both groups. Results: While no significant difference was found in the genotype distribution of the three polymorphisms between the patient and control groups, significant results were obtained in Bsm-I and Taq-I allele frequencies (Odds ratio=0.489; CI95%=0.275-0.871 and 0.519; CI95%=0.280-0.964) (p<0.05). Conclusions: In this study, we found that the frequency of allele “A” for Bsm-I and allele “C” for Taq-I was lower in the patient group. Contrary to most publications in the literature, polymorphisms were not found to be risk factors in our study.
- 31 October 2022
- Published by Marmara University in Marmara Medical Journal
- Vol. 35 (3) , 270-274
Vitamin D receptor gene polymorphisms in pediatric patients with leukemia-lymphoma: Does it have an impact on malignancy?
Objective: Genetic variations have been identified in specific regions of the Vitamin D receptor (VDR) gene and many studies were investigating whether these variations are associated with malignancy. Studies in the VDR on children are scarce. In this study, we aimed to investigate the VDR gene polymorphisms in pediatric patients with the diagnosis of leukemia and lymphoma. Patients and Methods: Of the 99 participants included in this cross-sectional study, 59 were control, 40 were patients. Fok-I, Bsm-I and Taq-I polymorphism of the VDR gene were investigated in both groups. Results: While no significant difference was found in the genotype distribution of the three polymorphisms between the patient and control groups, significant results were obtained in Bsm-I and Taq-I allele frequencies (Odds ratio=0.489; CI95%=0.275-0.871 and 0.519; CI95%=0.280-0.964) (p<0.05). Conclusions: In this study, we found that the frequency of allele “A” for Bsm-I and allele “C” for Taq-I was lower in the patient group. Contrary to most publications in the literature, polymorphisms were not found to be risk factors in our study.
- Open Access
- 1 June 2022
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 25 (1) , 41-50
Vitamin D receptor polymorphisms among the Turkish population are associated with multiple sclerosis
Multiple sclerosis (MS) is an inflammatory disease characterized by demyelination and axonal degeneration affecting the central nervous system. Among the genetic factors suggested to be associated with this disease are polymorphisms to the vitamin D receptor (VDR) gene. We tested the hypothesis that polymorphisms in the vitamin D receptor (VDR) gene are associated with MS. The aim of the study was to investigate the relationship of MS with the VDR gene Fok-I, Bsm-I and Taq-I polymorphisms among the Turkish population. This study contains 271 MS patients and 203 healthy controls. Genomic DNA was isolated from the samples and the VDR gene Fok-I, Bsm-I and Taq-I polymorphism regions were amplified by polymerase chain reaction (PCR). The PCR products were digested, and the genotypes were determined based on size of digested PCR products. Our results demonstrate associations between MS and the distribution of the VDR gene Fok-I T/T polymorphism genotype in a dominant model, VDR gene Fok-I T allele frequency, distribution of VDR gene Taq-I C/C polymorphism genotype in a dominant model and VDR gene Taq-I C allele frequency (Pearson test, p0.05) or allele frequency (Pearson test, p>0.05). Fok-I and Taq-I VDR gene polymorphisms are significantly associated with MS in dominant, homozygote and heterozygote inheritance models among the Turkish population.
- 1 June 2022
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 25 (1) , 41-50
Open AccessVitamin D receptor polymorphisms among the Turkish population are associated with multiple sclerosis
Multiple sclerosis (MS) is an inflammatory disease characterized by demyelination and axonal degeneration affecting the central nervous system. Among the genetic factors suggested to be associated with this disease are polymorphisms to the vitamin D receptor (VDR) gene. We tested the hypothesis that polymorphisms in the vitamin D receptor (VDR) gene are associated with MS. The aim of the study was to investigate the relationship of MS with the VDR gene Fok-I, Bsm-I and Taq-I polymorphisms among the Turkish population. This study contains 271 MS patients and 203 healthy controls. Genomic DNA was isolated from the samples and the VDR gene Fok-I, Bsm-I and Taq-I polymorphism regions were amplified by polymerase chain reaction (PCR). The PCR products were digested, and the genotypes were determined based on size of digested PCR products. Our results demonstrate associations between MS and the distribution of the VDR gene Fok-I T/T polymorphism genotype in a dominant model, VDR gene Fok-I T allele frequency, distribution of VDR gene Taq-I C/C polymorphism genotype in a dominant model and VDR gene Taq-I C allele frequency (Pearson test, p0.05) or allele frequency (Pearson test, p>0.05). Fok-I and Taq-I VDR gene polymorphisms are significantly associated with MS in dominant, homozygote and heterozygote inheritance models among the Turkish population.
- 27 April 2022
- Published by S. Karger AG in Molecular Syndromology
- Vol. 13 (5) , 447-453
First Patient Diagnosed as Feingold Syndrome Type 2 with Alport Syndrome and Review of the Current Literature
Introduction: Feingold syndrome type 2 (FGLDS2) is an ultra-rare genetic disorder characterized by short stature, microcephaly, digital abnormalities, and intellectual disability. Until now, 22 patients have been reported in the literature. FGLDS2 is caused by a germline heterozygous deletion of 13q resulting in haploinsufficiency of the MIR17HG gene. Case report: In the present study, we evaluated clinical, radiological, and genetic analyses of a 10-year-old Turkish-origin girl with short stature, brachydactyly, intellectual disability, hematuria, and proteinuria. Conclusion/Discussion: In the array-CGH analysis, a 15.7-Mb deletion, arr[hg19] 13q22q31.3(78,241,132_93,967,288)×1, was detected, and this alteration was evaluated to be pathogenic. The deletion of this region covering the MIR17HG gene is a potential cause of FGLDS2. Also, at her clinical exome sequencing study, a heterozygous c.2023G>A p.(Gly675Ser) variation was detected in the COL4A5 gene (NM_000495.4) that was likely pathogenic in up-to-date databases. As a result, we report on a patient who has FGLDS2 and Alport syndrome. This is the first report of a Turkish-origin FGLDS2 patient. Reporting new cases expands the range of phenotypes, plays a crucial role in understanding the FGLDS2 pathogenesis, and is important in terms of screening at-risk family members for giving appropriate genetic counseling and preimplantation genetic diagnosis opportunities.
- 27 April 2022
- Published by S. Karger AG in Molecular Syndromology
- Vol. 13 (5) , 447-453
First Patient Diagnosed as Feingold Syndrome Type 2 with Alport Syndrome and Review of the Current Literature
Introduction: Feingold syndrome type 2 (FGLDS2) is an ultra-rare genetic disorder characterized by short stature, microcephaly, digital abnormalities, and intellectual disability. Until now, 22 patients have been reported in the literature. FGLDS2 is caused by a germline heterozygous deletion of 13q resulting in haploinsufficiency of the MIR17HG gene. Case report: In the present study, we evaluated clinical, radiological, and genetic analyses of a 10-year-old Turkish-origin girl with short stature, brachydactyly, intellectual disability, hematuria, and proteinuria. Conclusion/Discussion: In the array-CGH analysis, a 15.7-Mb deletion, arr[hg19] 13q22q31.3(78,241,132_93,967,288)×1, was detected, and this alteration was evaluated to be pathogenic. The deletion of this region covering the MIR17HG gene is a potential cause of FGLDS2. Also, at her clinical exome sequencing study, a heterozygous c.2023G>A p.(Gly675Ser) variation was detected in the COL4A5 gene (NM_000495.4) that was likely pathogenic in up-to-date databases. As a result, we report on a patient who has FGLDS2 and Alport syndrome. This is the first report of a Turkish-origin FGLDS2 patient. Reporting new cases expands the range of phenotypes, plays a crucial role in understanding the FGLDS2 pathogenesis, and is important in terms of screening at-risk family members for giving appropriate genetic counseling and preimplantation genetic diagnosis opportunities.
- 1 April 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 12 (3) , 179-185
Biallelic Mutations in DNAJB11are Associated with Prenatal Polycystic Kidney Disease in a Turkish Family
Polycystic kidney disease (PKD) is a life-threatening condition resulting in end-stage renal disease. Two major forms of PKD are defined according to the inheritance pattern. Autosomal dominant PKD (ADPKD) is characterized by renal cysts, where nearly half of the patients suffers from renal failure in the 7th decade of life. Autosomal recessive PKD (ARPKD) is a rarer and more severe form presenting in childhood. Whole-exome sequencing (WES) analyses was performed to investigate molecular causes of the disease in the fetus. In this study, we present 2 fetuses prenatally diagnosed with PKD in a consanguineous family. WES analysis of the second fetus revealed a homozygous variant (c.740+1G>A) in DNAJB11 which is related to ADPKD. This study reveals that DNAJB11 biallelic mutations may cause an antenatal severe form of ARPKD and contributes to understanding the DNAJB11-related ADPKD phenotype. The possibility of ARPKD due to biallelic mutations in ADPKD genes should be considered in genetic counseling.
- 1 April 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 12 (3) , 179-185
Biallelic Mutations in DNAJB11are Associated with Prenatal Polycystic Kidney Disease in a Turkish Family
Polycystic kidney disease (PKD) is a life-threatening condition resulting in end-stage renal disease. Two major forms of PKD are defined according to the inheritance pattern. Autosomal dominant PKD (ADPKD) is characterized by renal cysts, where nearly half of the patients suffers from renal failure in the 7th decade of life. Autosomal recessive PKD (ARPKD) is a rarer and more severe form presenting in childhood. Whole-exome sequencing (WES) analyses was performed to investigate molecular causes of the disease in the fetus. In this study, we present 2 fetuses prenatally diagnosed with PKD in a consanguineous family. WES analysis of the second fetus revealed a homozygous variant (c.740+1G>A) in DNAJB11 which is related to ADPKD. This study reveals that DNAJB11 biallelic mutations may cause an antenatal severe form of ARPKD and contributes to understanding the DNAJB11-related ADPKD phenotype. The possibility of ARPKD due to biallelic mutations in ADPKD genes should be considered in genetic counseling.